Study details
Enrolling now
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
City of Hope Medical Center
NCT IDNCT05204147ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
20
Study length
about 4.1 years
Ages
18+
Locations
1 site in CA
What this study is about
This trial is testing the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with advanced cancer. Ac225-DOTA-M5A is a radioactive antibody that targets CEA positive cancer cells to kill them.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A
- 2.Undergo Biospecimen Collection
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Incidence of adverse events, Maximum tolerated dose (MTD)
Secondary: Best overall response, Overall survival, Progression-free survival
Procedures
diagnostic